Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 15
Original Research
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 3,174 | Dovepress* | 2,881+ | 110 | 2,991 | |
| PubMed Central* | 293 | 92 | 385 | ||
| Totals | 3,174 | 202 | 3,376 | ||
| *Since 6 November 2023 | |||||
View citations on PubMed Central and Google Scholar